Abhijit Lele &Amp; Sohini Das

Stories by Abhijit Lele &Amp; Sohini Das

'Mercedes To Launch 10 Cars In 2023'

'Mercedes To Launch 10 Cars In 2023'

Rediff.com   3 Jul 2023

'And a majority will be in the top-end vehicle range.'

By 2025 Indian Trucks Will Have AC Cabin

By 2025 Indian Trucks Will Have AC Cabin

Rediff.com   3 Jul 2023

'Instead of ACs, the government should do something to increase our salary.'

2,300 Indian Students Return To Ukraine!

2,300 Indian Students Return To Ukraine!

Rediff.com   29 Jun 2023

About half of the students, who have been affected by the war, have taken admission to universities in other countries.

Regulatory woes torpedo PE/VC deals in e-pharma sector

Regulatory woes torpedo PE/VC deals in e-pharma sector

Rediff.com   27 Jun 2023

With regulatory uncertainties clouding the future of online pharmacies, deals in the space are showing signs of slowdown, as also fresh investment from private-equity (PE) firms and venture capitalists (VCs). The data from Venture Intelligence shows so far in 2023 (as of June 13) there has been one deal with PE-VC funding. In 2022 there were four, a sharp fall from the 12, totalling $1,520 million, the sector had attracted in 2021.

US drug shortage a shot in the arm for Indian pharmaceutical companies

US drug shortage a shot in the arm for Indian pharmaceutical companies

Rediff.com   26 Jun 2023

Drug shortages in the US are at an all-time high, and price erosion has stabilised, which could benefit Indian pharmaceutical (pharma) companies with a US focus, according to analysts. Nuvama Research analysts said that US price erosion seems to have normalised to its old levels of 6-8 per cent and volumes are picking up with easing of inventory. Similarly, an ICICIdirect analyst noted: "Price erosion intensity has now moderated to a single digit and is expected to tone down a

Nigeria flags 2 India-made drugs as substandard, having toxins

Nigeria flags 2 India-made drugs as substandard, having toxins

Rediff.com   20 Jun 2023

Oral paracetamol and another cough medicine manufactured by companies based in Mumbai and Punjab were found to be "sub-standard or found to be containing toxins", reports Sohini Das.

Can Maruti Jimny Compete With The Thar?

Can Maruti Jimny Compete With The Thar?

Rediff.com   20 Jun 2023

Jimny will be priced between Rs 12.7 lakh and Rs 15.05 lakh.

Better chip supply fuels passenger vehicle production by 16%: Siam

Better chip supply fuels passenger vehicle production by 16%: Siam

Rediff.com   14 Jun 2023

Amid better semiconductor chip supplies, the Indian automotive industry posted an 8 percent growth in production of vehicles across categories for the month of May, with three-wheelers (20 per cent) and passenger vehicles (16 per cent) leading the pack. Exports, however, dipped 21 per cent at an industry level. The industry also recorded its highest-ever May wholesales of domestic passenger vehicles (334,802 units), riding on high demand for sport utility vehicles (SUVs) and better supplies of semiconductor chips.

Under the lens: Regulator moots pre-export govt testing for cough syrup cos

Under the lens: Regulator moots pre-export govt testing for cough syrup cos

Rediff.com   24 May 2023

After reports of contamination in cough syrups sent from the country, India is considering a system to test them before exporting. It is learnt that the Central Drugs Standard Control Organisation (CDSCO) has sent a proposal to the Union health ministry on this. The idea is to test the medicines at government labs before exporting.

Bank of Baroda makes Rs 500 crore provision for Go First exposure

Bank of Baroda makes Rs 500 crore provision for Go First exposure

Rediff.com   17 May 2023

Bank of Baroda (BoB) has made prudential provision of Rs 500 crore for exposure to Go First, which has sought bankruptcy protection after the National Company Law Tribunal (NCLT) admitted its plea for voluntary insolvency. Sanjiv Chadha, managing director and chief executive officer of BoB, said the bank identifies issues in advance and makes provisions if required. The Mumbai-based public sector lender has an exposure of Rs 1,300 crore to the troubled airline.

Drug sales stuck at pre-pandemic level, price rise shapes market growth

Drug sales stuck at pre-pandemic level, price rise shapes market growth

Rediff.com   16 May 2023

Drug sale volumes are almost stuck at pre-pandemic levels but price growth has improved value, data from market research agency Pharmarack AWACS showed. The Indian pharmaceutical market's (IPM) volumes in April 2023 grew by 0.21 per cent when compared to April 2019. Key therapy areas like cardiac, anti-diabetic and vitamins recorded negative volume or consumption growth, while respiratory, anti-infectives, and pain and analgesics had positive growth from April 2019 to April this year.

Q4 results: Private sector banks post 9.7% decline in net profit

Q4 results: Private sector banks post 9.7% decline in net profit

Rediff.com   10 May 2023

Private sector banks reported a robust profile with healthy growth in net interest income (NII), credit offtake and reduction in provision burden for the fourth quarter ended March 2023 (Q4 of FY23). However, as a pack, their net profit declined by 9.7 per cent year-on-year (YoY) at Rs 25,317 crore in Q4. This is because Axis Bank posted losses due to its one-time hefty charge for the acquisition of Citibank India's consumer business.

Mahindra and Mahindra gears up for EV play; aims to make 200,000 EVs a year

Mahindra and Mahindra gears up for EV play; aims to make 200,000 EVs a year

Rediff.com   9 May 2023

Analysts have predicted a 23 per cent volume growth for the auto segment between FY22 and FY25, riding on the company's differentiated EV and SUV plan. M&M is already a market leader with a 36 per cent share in electric three-wheelers, and its Zaheerabad plant in Telangana is ready to cater to demand. In the farm segment, the company plans to focus on niche electric products.

Import of key Chinese medical devices rises up to 152% till Dec FY23

Import of key Chinese medical devices rises up to 152% till Dec FY23

Rediff.com   5 May 2023

In the first nine months of financial year 2022-23, India's exports of medical devices have grown by 17 per cent, while imports have declined by around 8 per cent, show the latest data compiled by the Association of Indian Medical Device Industry (AiMeD). However, import of 30 medical devices from China has risen between 25 per cent and 152 per cent during this period, the AiMeD has written to Commerce and Industries Minister Piyush Goyal in March. The AiMeD is an umbrella organisation of medical device makers.

Can Jaguar Land Rover Meet its EV Target by 2030?

Can Jaguar Land Rover Meet its EV Target by 2030?

Rediff.com   29 Apr 2023

The question is: Will the company have a strong balance sheet to support this massive investment plan?

It's Raining Discounts For Car Buyers

It's Raining Discounts For Car Buyers

Rediff.com   28 Apr 2023

Dealers across brands are slashing prices by Rs 20,000 to over Rs 1 lakh, depending on the car model.

India business to put a spring in pharma's step

India business to put a spring in pharma's step

Rediff.com   26 Apr 2023

Hospitals to recover from sluggish Q3; diagnostics' growth rate at pre-Covid levels.

Why Covishield Production Has Resumed

Why Covishield Production Has Resumed

Rediff.com   20 Apr 2023

'I understand some people are comfortable getting a Covishield shot as their third dose.'

SBI seeks clarity from SC on granting personal hearing for defaulters

SBI seeks clarity from SC on granting personal hearing for defaulters

Rediff.com   17 Apr 2023

SBI has suggested that banks be exempted from handing over the complete forensic audit report to the borrower as it would hamper future investigation and forewarn the borrower by way of disclosure of confidential information.

Better net interest margins likely to help bottom line of banks in Q4

Better net interest margins likely to help bottom line of banks in Q4

Rediff.com   15 Apr 2023

Benefitting from the economic rebound, banks are expected to report a healthy bottom-line and asset quality profile in the quarter ended March 2023 (Q4FY23). The net profit of listed commercial banks is projected to grow by an average 43.6 per cent year-on-year (YoY) in Q4FY23 amid better net interest margins (NIMs) and declining credit costs. This is based on a combined assessment of analyst estimates for 17 banks on Bloomberg database.